SHINE Medical Technologies LLC today announced that the U.S. Nuclear Regulatory Commission (NRC) has accepted SHINE’s Operating License Application to operate its medical isotope production facility in Janesville, Wis. The NRC’s acceptance confirms that SHINE’s application was complete and of sufficient quality for the NRC to start its detailed technical review of the application. The next step involves the NRC conducting a regulatory audit to determine a detailed schedule for the remainder of the review.
SHINE’s application seeks regulatory approval to operate its transformational non-reactor technology that will produce essential medical isotopes, including molybdenum-99, or Mo-99, which is used in more than 40 million medical procedures every year. The facility will be capable of supplying two-thirds of the U.S. patient demand for the isotope. SHINE broke ground on construction in May. Read the full story here.